Differential effects of statins on relevant functions of human monocyte-derived dendritic cells

Journal of Leukocyte Biology

Volumn 79, Issue 3, 2006, Pages 529-538

  Yilmaz, Atilla ^a   Reiss, Christine ^a   Weng, Alexander ^a   Cicha, Iwona ^a   Stumpf, Christian ^a   Steinkasserer, Alexander ^a   Daniel, Werner G ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Atherosclerosis; Immunity; Inflammation

Indexed keywords

ATORVASTATIN; CD40 ANTIGEN; CD71 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; SIMVASTATIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; MEMBRANE ANTIGEN; TOLL LIKE RECEPTOR;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANTIGEN PRESENTATION; ATHEROSCLEROSIS; CELL CULTURE; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOPHYSIOLOGY; SECRETION;

ANTIGEN PRESENTATION; ANTIGENS, SURFACE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MONOCYTES; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 33646096764     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0205064     Document Type: Article

References (46)

1. Vaughan, C. J., Gotto, A. M. (2004) Update on statins: 2003. Circulation 110, 886-892.
2. Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333, 621-627.
3. Kwak, B., Mulhaupt, F., Myit, S., Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402.
4. 1 cells through atorvastatin. J. Exp. Med. 197, 725-733.
5. Youssef, S., Stuve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., Zamvil, S. S. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84.
6. Merx, M. W., Liehn, E. A., Janssens, U., Lutticken, R., Schrader, J., Hanrath, P., Weber, C. (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109, 2560-2565.
7. Shimizu, K., Aikawa, M., Takayama, K., Libby, P., Mitchell, R. N. (2003) Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108, 2113-2120.
8. 2 development. Circ. Res. 93, 948-956.
9. Fehr, T., Kahlert, C., Fierz, W., Joller-Jemelka, H. I., Riesen, W. F., Rickli, H., Wuthrich, R. P., Ammann, P. (2004) Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175, 83-90.
10. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., Palucka, K. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811.
11. Bobryshev, Y. V., Lord, R. S. (1995) Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of normal aorta. Arch. Histol. Cytol. 58, 307-322.
12. Bobryshev, Y. V., Lord, R. S. (1995) S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc. Res. 29, 689-696.
13. Alderman, C. J., Bunyard, P. R., Chain, B. M., Foreman, J. C., Leake, D. S., Katz, D. R. (2002) Effects of oxidized low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc. Res. 55, 806-819.
14. Coutant, F., Agaugue, S., Perrin-Cocon, L., Andre, P., Lotteau, V. (2004) Sensing environmental lipids by dendritic cell modulates its function. J. Immunol. 172, 54-60.
15. Aicher, A., Heeschen, C., Mohaupt, M., Cooke, J. P., Zeiher, A. M., Dimmeler, S. (2003) Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 107, 604-611.
16. Nahmod, K. A., Vermeulen, M. E., Raiden, S., Salamone, G., Gamberale, R., Fernandez-Calotti, P., Alvarez, A., Nahmod, V., Giordano, M., Geffner, J. R. (2003) Control of dendritic cell differentiation by angiotensin II. FASEB J. 17, 491-493.
17. Yilmaz, A., Lochno, M., Traeg, F., Cicha, I., Reiss, C., Stumpf, C., Raaz, D., Anger, T., Amann, K., Probst, T., Ludwig, J., Daniel, W. G., Garlichs, C. D. (2004) Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176, 101-110.
18. Weis, M., Schlichting, C. L., Engleman, E. G., Cooke, J. P. (2002) Endothelial determinants of dendritic cell adhesion and migration. New implications for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 22, 1817-1823.
19. Angeli, V., Llodra, J., Rong, J. X., Satoh, K., Ishii, S., Shimizu, T., Fisher, E. A., Randolph, G. J. (2004) Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21, 561-574.
20. Yilmaz, A., Reiss, C., Tantawi, O., Wenig, A., Stumpf, C., Raaz, D., Ludwig, J., Berger, T., Steinkasserer, A., Daniel, W. G., Garlichs, C. D. (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172, 85-93.
21. Sun, D., Fernandes, G. (2003) Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates pro-inflammatory cytokine production. Cell. Immunol. 223, 52-62.
22. Jakobisiak, M., Bruno, S., Skierski, J. S., Darzynkiewicz, Z. (1991) Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA 88, 3628-3632.
23. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D., Schuler, G. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151.
24. Sallusto, F., Cella, M., Danieli, C., Lanzavecchia, A. (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400.
25. Lyons, A. B., Parish, C. R. (1994) Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171, 131-137.
26. Iwasaki, A., Medzhitov, R. (2004) Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995.
27. Edfeldt, K., Swedenborg, J., Hansson, G. K., Yan, Z. Q. (2002) Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161.
28. Michelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., Arditi, M. (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA 101, 10679-10684.
29. Kiechl, S., Lorenz, E., Reindl, M., Wiedermann, C. J., Oberhollenzer, F., Bonora, E., Willeit, J., Schwartz, D. A. (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192.
30. Muzio, M., Bosisio, D., Polentarutti, N., D'Amico, G., Stoppacciaro, A., Mancinelli, R., Veer, C., Penton-Rol, G., Ruco, L. P., Allavena, P., Mantovani, A. (2000) Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR-3 in dendritic cells. J. Immunol. 164, 5998-6004.
31. Cario, E., Podolsky, D. K. (2000) Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR-3) and TLR-4 in inflammatory bowel disease. Infect. Immun. 68, 7010-7017.
32. Hackstein, H., Taner, T., Logar, A. J., Thomson, A. W. (2002) Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 100, 1084-1087.
33. Bellosta, S., Bernini, F., Ferri, N., Quarato, P., Canavesi, M., Arnaboldi, L., Fumagalli, R., Paoletti, R., Corsini, A. (1998) Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 137 (Suppl.), S101-S109.
34. Llorente-Cortes, V., Martinez-Gonzalez, J., Badimon, L. (1998) Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 18, 738-746.
35. Hansson, G. K. (2001) Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 1876-1890.
36. Kiener, P. A., Davis, P. M., Murray, J. L., Youssef, S., Rankin, B. M., Kowala, M. (2001) Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol. 1, 105-118.
37. Monick, M. M., Powers, L. S., Butler, N. S., Hunninghake, G. W. (2003) Inhibition of Rho family GTPases results in increased TNF-α production after lipopolysaccharide exposure. J. Immunol. 171, 2625-2630.
38. Matsumoto, M., Einhaus, D., Gold, E. S., Aderem, A. (2004) Simvastatin augments lipopolysaccharide-induced pro-inflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 172, 7377-7384.
39. Rezaie-Majd, A., Maca, T., Bucek, R. A., Valent, P., Muller, M. R., Husslein, P., Kashanipour, A., Minar, E., Baghestanian, M. (2002) Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22, 1194-1199.
40. Pleiner, J., Schaller, G., Mittermayer, F., Zorn, S., Marsik, C., Polterauer, S., Kapiotis, S., Wolzt, M. (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110, 3349-3354.
41. Steiner, S., Speidl, W. S., Pleiner, J., Seidinger, D., Zorn, G., Kaun, C., Wojta, J., Huber, K., Minar, E., Wolzt, M., Kopp, C. W. (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111, 1841-1846.
42. Liappis, A. P., Kan, V. L., Rochester, C. G., Simon, G. L. (2001) The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis. 33, 1352-1357.
43. Almog, Y., Shefer, A., Novack, V., Maimon, N., Barski, L., Eizinger, M., Friger, M., Zeller, L., Danon, A. (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110, 880-885.
44. Nguyen, X. D., Eichler, H., Dugrillon, A., Piechaczek, C., Braun, M., Klüter, H. (2003) Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J. Immunol. Methods 275, 57-68.
45. Reddy, M., Eirikis, E., Davis, C., Davis, H. M., Prabhakar, U. (2004) Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J. Immunol. Methods 293, 127-142.
46. Pentikainen, P. J., Saraheimo, M., Schwartz, J. I., Amin, R. D., Schwartz, M. S., Brunner-Ferber, F., Rogers, J. D. (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol. 32, 136-140.